Inclusion Criteria:

        Part A • With advanced solid malignancies who are not eligible for standard therapy or for
        whom standard therapy has failed

        Part B

        • With histologically or cytologically confirmed NSCLC of stage IIIB or IV (per 7th
        International Association for the Study of Lung Cancer classification) that has progressed
        after one line of platinum containing doublet chemotherapy

        Part A and B

          -  Willingness and feasibility to provide a tumor biopsy sample both at screening and
             during treatment (If archived tumor material not older than 1 year is available, then
             the screening biopsy will not be performed).

          -  Participants with prior radiation therapy must have measurable disease in
             non-irradiated sites or documented evidence of progression within the radiation field.

          -  With known central nervous system (CNS) must have completed primary brain therapy
             (such as whole brain radiotherapy, stereotactic radiosurgery, or complete surgical
             resection) and must have remained clinically stable, asymptomatic, and without steroid
             treatment for at least 21 days.

        Exclusion Criteria:

          -  Not recovered (i.e. toxicity grade >1) from prior investigational drug and/or
             anti-cancer therapy (chemo- or palliative radiotherapy).

          -  Symptomatic and/or progressive brain metastasis or carcinomatous meningitis.

          -  Immunosuppressive agents (such as steroids) for any reason should be tapered off
             before initiation of study treatment (except low-dose prednisone at a total dose of up
             to 10 mg/day).

        Part B only

          -  Tumor activating epidermal growth factor receptor (EGFR) mutation(s) or anaplastic
             lymphoma kinase (ALK)/ROS1 translocation/rearrangement (testing required in
             non-squamous participants if status is unknown).

          -  More than one prior line of chemotherapy and one line of anti-PD1/PDL1 therapy.